Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RRM2 siRNA
- Development stage
- Preclinical
- Lead developer
- Calando Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
RRM2 siRNA refers to a class of RNA interference (RNAi) therapeutics designed to silence the expression of the ribonucleotide reductase regulatory subunit M2 (RRM2). RRM2 is a rate-limiting enzyme in the production of deoxyribonucleotide triphosphates (dNTPs), which are essential for DNA synthesis and repair. Because RRM2 is frequently overexpressed in various cancers and is associated with poor prognosis and treatment resistance, it is a significant target for oncology. The most prominent clinical-stage candidate in this category was CALAA-01, developed by Calando Pharmaceuticals, which utilized a cyclodextrin-based nanoparticle delivery system. While CALAA-01 demonstrated the feasibility of systemic siRNA delivery in humans during Phase I trials, the development of RRM2-targeted siRNAs continues primarily in research settings, exploring their potential as radiosensitizers and chemosensitizers in indications such as glioblastoma, pancreatic cancer, and solid tumors.
- Other names
- RRM2-targeted siRNARRM-2-targeted siRNARRM 2-targeted siRNAsiRRM2siRRM-2siRRM 2
02
Targets
RRM2
Beyond the preview
Go deeper on RRM2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RRM2 siRNA.